The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
Avastin (bevacizumab) [product information].San Francisco, CA: Genentech Inc.; February 2004.
2.
KabbinavarF., HurwitzH., FehrenbacherL.Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol.2003; 21(1): 60–5.
3.
HurwitzH., FehrenbacherL., NovotnyW.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med.2004; 350(23): 2335–42.
4.
GiantonioB.J., CatalanoP.J., MeropolN.J.The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (adv CRC): An updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) [abstract 241]. Eastern Cooperative Oncology Group Study E3200. American Society of Clinical Oncology Gastrointestinal Cancer Symposium; 2004.
5.
LangmuirV.K., CobleighM.A., HerbstR.S.Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Am Soc Clin Oncol.2002a; 21: 9a.
6.
BursteinH.J., ParkerL.M., SavoieJ.Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Can Res Treat.2002a; 76: S115.
7.
RamaswamyB., RhoadesC.A., KendraK.CTEP-sponsored Phase II Trial of Bevacizumab in Combination with Docetaxel in Metastatic Breast Cancer. Breast Cancer Res Treat.2003; 28: S50.
8.
YangJ.C., HaworthL., SherryR.M.A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med.2003; 349(5): 427–34.
9.
DeVoreR., HehrenbacherL., HerbstR.A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC [Abstract 1896]. Presented at the 36th Annual meeting of the American Society of Clinical Oncology; May 20–23, 2000. New Orleans, Louisiana.
10.
KindlerH.L., AnsariR., LesterE.Bevacizumab plus gemcitabine in patients with advanced pancreatic cancer [abstract 1037]. Proc Am Soc Clin Oncol.2003; 22: 259.
11.
BaselgaJ.The EGFR as a target for anticancer therapy — focus on cetuximab. Eur J Cancer.2001; 37: S16–S22.
Erbitux (cetuximab) [product information].Branchburg, NJ: ImClone Systems Incorporated; February 2004.
14.
SaltzL.B., MeropolN.J., LoehrerP.J.Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol.2004; 22(7): 1201–8.
15.
SchoffskiP., LutzM.P., FolprechtG.Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer, that expresses epidermal growth factor receptor [abstract 633]. Proc Am Soc Clin Oncol.2002; 21: 15a.
16.
SaltzL., RubinM., HochsterH.Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract 7]. Proc Am Soc Clin Oncol.2001; 20: 3a.
17.
ShinD.M., DonatoN.J., Perez-SolerR.Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Can Res.2001; 7: 1204–13.
18.
BurtnessB.A., LiY., FloodW.Phase III trial comparing cisplatin(C) plus placebo (P) to C plus anti-epidermal growth factor antibody (EGF-R) C225 in patients with metastatic/recurrent head and neck cancer (HNC) [abstract 901]. Proc Am Soc Clin Oncol.2002; 21.
19.
KiesM.S., ArquetteM.A., NabellL.Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin congaing chemotherapy [abstract 925]. Proc Am Soc Clin Oncol.2002; 21.
20.
KimE.S., MauerA.M., FossellaF.V.A phase II study of Erbitux (IMC-225), and epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC) [abstract 1169]. Proc Am Soc Clin Oncol.2002; 21.
21.
MotzerR.J., AmatoR., ToddM.Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs.2003; 21: 99–101.
